|
Market Closed -
Nasdaq
01:30:00 29/10/2026 am IST
|
5-day change | 1st Jan Change | ||
| 2.560 USD | -2.66% |
|
-10.18% | +80.28% |
| 15/10 | Edesa Biotech, Inc. Receives FDA IND Clearance For Phase 2 Clinical Study Of EB06 In Vitiligo | CI |
| 20/08 | Edesa Biotech Launches Public Offering of Common Shares, Warrants | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Bio Therapeutic Drugs
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 3.55Cr | - | - | - | - | - |
| 6.35TCr | |||||
| 5.45TCr | |||||
| 5.36TCr | |||||
| 4.48TCr | |||||
| 4.16TCr |
- Stock Market
- Stocks
- EDSA Stock
- Charts Edesa Biotech, Inc.
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
